|
|
|
| Clinical Effect of Xianling Gubao Capsule Combined with Estrogen Replacement Therapy on Perimenopausal Syndrome Patients |
| LI Xiao-wen, ZHANG Wei-tao, XU Jin-ping, et al |
| Department of Laboratory Medicine, Feicheng Mining Center Hospital, Feicheng Shandong 271608 |
|
|
|
|
Abstract 【Objective】 To investigate the influences of Xianling Gubao capsule combined with estrogen replacement therapy on the clinical symptoms, bone density and serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) in perimenopausal syndrome patients. 【Methods】 Eighty-two cases of patients with perimenopausal syndrome in our hospital from August 2016 to August 2017 were selected. Patients were divided into the observation group and the control group by random alphabet. The control group was treated with estrogen replacement therapy, while the observation group was treated with Xianling Gubao capsule in addition to estrogen replacement. The therapeutic effect, adverse reactions and clinical symptoms improvement of the two groups were compared The bone mineral density and serum FSH, LH and estradiol (E2) levels were measured and compared before and after treatment. 【Results】 The effective rate of the observation group was 97.56% (40/41), which was significantly higher than 80.49% (33/41) of the control group (P<0.05). Kupperman score of the observation group was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). Compared to the control group, the mean vertebral bone density and mean femoral neck bone density were higher in the observation group (P<0.05). In comparison with the control group, the serum FSH and LH levels in the observation group were significantly decreased, while serum E2 level increased significantly (P<0.05); the incidence of adverse reactions in the observation group(4.88%) was significantly lower than that in the control group(24.39%), and the difference was statistically significant (P<0.05). 【Conclusion】 The application of Xianling Gubao capsule combined with estrogen replacement therapy has achieved satisfactory clinical effect in the treatment of perimenopausal syndrome, which clinical symptoms are relieved, bone density is increased significantly, the levels of serum FSH and LH are improved. It can promote the effective recovery of ovarian function, at the same time, there was no obvious adverse reaction.
|
|
Received: 27 September 2019
|
|
|
|
|
|
[1] 刘曲慧,孙小翠.更年舒片联合替勃龙片对围绝经期综合征患者血脂代谢及激素水平的影响[J].中医学报,2016,31(6):889-891.
[2] 李振兴,何若苹.何若苹治疗围绝经期综合征经验浅析[J].浙江中医药大学学报,2018,42(2):108-110.
[3] 曹泽毅.中华妇产科学[M].第2版.北京:人民卫生出版社,2005:2537.
[4] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,2012:241.
[5] 王淑玉.实用妇产科诊疗规范[M].南京:江苏科学技术出版社,2003:120.
[6] 薛薇,邓燕,王艳芳,等.低剂量与标准剂量结合雌激素联合天然孕酮或地屈孕酮治疗围绝经期综合征的疗效观察[J].实用妇产科杂志,2017,33(5):388-391.
[7] Jones SM,Guthrie KA,Lacroix AZ,et al.Is heart rate variability associated with frequency and intensity of vasomotor symptoms among healthy perimenopausal and postmenopausal women [J].Clin Auton Res,2016,26(1):7-13.
[8] 杨柳,侯海燕,孟珠,等.围绝经期综合征睑板腺功能障碍患者的眼表及睑板腺形态和功能表现[J].中华实验眼科杂志,2016,34(11):1014-1018.
[9] 张帅,李浩,王志勇,等.基于“阴阳-气血-营卫”理论探讨围绝经期综合征病机[J].中华中医药杂志,2018,33(2):466-469.
[10] 王秋琴,邵婕.低剂量雌激素替代疗法对围绝经期综合征患者激素水平及骨密度的影响[J].实用临床医药杂志,2016,20(24):63-65.
[11] Gravholt CH.Hormone replacement therapy in Turner syndrome is important—a new meta-analysis points at many shortcomings in the available literature[J].Endocrine,2017,55(2):329-330.
[12] 叶永梅,李新平.低剂量雌激素替代疗法治疗围绝经期综合征疗效及对Kupperman评分和激素水平的影响[J].海南医学院学报,2016,22(6):580-582.
[13] 王焕珍, 柴艺汇, 陈云志,等. 淫羊藿化学成分与药理作用研究进展[J].亚太传统医药, 2016, 12(7):63-65.
[14] 宋彦茹, 卢叶青, 路静,等. 仙灵骨葆胶囊联合谷维素在围绝经期妇女中的应用[J].中国煤炭工业医学杂志, 2013, 16(12):1974-1976.
[15] 任光友, 周宁, 张贵林,等. 仙灵骨葆胶囊对多种动物病理模型性激素及性腺的影响[J].中外健康文摘, 2009, 6(10):8-9.
[16] 叶喜阳, 邓宇傲, 马利国,等. 仙灵骨葆胶囊植物雌激素活性的临床观察[J].福建医科大学学报, 2010, 44(2):137-139. |
|
|
|
2020, Vol. 37 
